Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1 / 2 (CIMBA)
Mount Sinai Hospital · Mount Sinai Hospital · +21 more institutions
Abstract
Previously, small studies have found that BRCA1 and BRCA2 breast tumors differ in their pathology. Analysis of larger datasets of mutation carriers should allow further tumor characterization.
We used data from 4,325 BRCA1 and 2,568 BRCA2 mutation carriers to analyze the pathology of invasive breast, ovarian, and contralateral breast cancers.
Citation impact
- FWCI
- 20.84
- Percentile
- 100%
- References
- 49
Authors
133- NMNasim MavaddatCorresponding
Mount Sinai Hospital, Mount Sinai Hospital, Memorial Sloan Kettering Cancer Center, Cancer Genetics (United States)
- DBDaniel Barrowdale
Mount Sinai Hospital, Mount Sinai Hospital, Memorial Sloan Kettering Cancer Center, Cancer Genetics (United States)
- ILIrene L. Andrulis
Mount Sinai Hospital, Mount Sinai Hospital, Memorial Sloan Kettering Cancer Center, Cancer Genetics (United States)
- SMSusan M. Domchek
Mount Sinai Hospital, Mount Sinai Hospital, Memorial Sloan Kettering Cancer Center, Cancer Genetics (United States)
- DEDiana Eccles
Mount Sinai Hospital, Mount Sinai Hospital, Memorial Sloan Kettering Cancer Center, Cancer Genetics (United States)
Topics & keywords
- Medicine
- Ovarian cancer
- Mutation
- Oncology
- Gynecology
- Internal medicine
- Breast cancer
- Pathology
- Good health and well-being